Sidney Kennedy


Scientist, Li Ka Shing Knowledge Institute

Research Programs


Dr. Sidney H. Kennedy is Professor of Psychiatry at the University of Toronto, the Arthur Sommer Rotenberg Chair in Suicide and Depression Studies, and a Scientist at Li Ka Shing Knowledge Institute and Toronto Western Research Institute, Toronto, Canada. Dr. Kennedy is the lead investigator for a large depression biomarker initiative. He has published extensively on new drug evaluation, neuroimaging and neurostimulation therapies, personality factors in depression, antidepressant effects on sexual function and treatment guidelines for Major Depressive Disorder and Bipolar Disorder.

Dr. Kennedy is the Immediate Past President of the International Society for Affective Disorders, former President of the Canadian College of Neuropsychopharmacology, and the founding chair of the Canadian Network for Mood and Anxiety Treatments (CANMAT).

He has published more than 350 peer reviewed publications and 11 books on depression and related topics.

Recent Publications

  1. Kennedy, SH, Klumpp, DA. Michael Additions Involving Amino Acid Esters with Alkenyl N-Heterocycles. J. Org. Chem. 2017; :. doi: 10.1021/acs.joc.7b01724. PubMed PMID:28846408 .
  2. Allega, OR, Leng, X, Vaccarino, A, Skelly, M, Lanzini, M, Hidalgo, MP et al.. Performance of the biological rhythms interview for assessment in neuropsychiatry: An item response theory and actigraphy analysis. J Affect Disord. 2017;225 :54-63. doi: 10.1016/j.jad.2017.07.047. PubMed PMID:28787704 .
  3. Farzan, F, Atluri, S, Frehlich, M, Dhami, P, Kleffner, K, Price, R et al.. Standardization of electroencephalography for multi-site, multi-platform and multi-investigator studies: insights from the canadian biomarker integration network in depression. Sci Rep. 2017;7 (1):7473. doi: 10.1038/s41598-017-07613-x. PubMed PMID:28785082 PubMed Central PMC5547036.
  4. Maciukiewicz, M, Marshe, VS, Tiwari, AK, Fonseka, TM, Freeman, N, Kennedy, JL et al.. Genome-wide association studies of placebo and duloxetine response in major depressive disorder. Pharmacogenomics J. 2017; :. doi: 10.1038/tpj.2017.29. PubMed PMID:28696415 .
  5. Bhat, V, Kennedy, SH. Recognition and management of antidepressant discontinuation syndrome. J Psychiatry Neurosci. 2017;42 (4):E7-E8. . PubMed PMID:28639936 PubMed Central PMC5487275.
  6. Leyton, M, Kennedy, SH. Neuroimaging tests for clinical psychiatry: Are we there yet?. J Psychiatry Neurosci. 2017;42 (4):219-221. . PubMed PMID:28639935 PubMed Central PMC5487268.
  7. Soczynska, JK, Kennedy, SH, Alsuwaidan, M, Mansur, RB, Li, M, McAndrews, MP et al.. A pilot, open-label, 8-week study evaluating the efficacy, safety and tolerability of adjunctive minocycline for the treatment of bipolar I/II depression. Bipolar Disord. 2017;19 (3):198-213. doi: 10.1111/bdi.12496. PubMed PMID:28599348 .
  8. McIntyre, RS, Lee, Y, Zhou, AJ, Rosenblat, JD, Peters, EM, Lam, RW et al.. The Efficacy of Psychostimulants in Major Depressive Episodes: A Systematic Review and Meta-Analysis. J Clin Psychopharmacol. 2017;37 (4):412-418. doi: 10.1097/JCP.0000000000000723. PubMed PMID:28590365 .
  9. Lopez, JP, Fiori, LM, Cruceanu, C, Lin, R, Labonte, B, Cates, HM et al.. MicroRNAs 146a/b-5 and 425-3p and 24-3p are markers of antidepressant response and regulate MAPK/Wnt-system genes. Nat Commun. 2017;8 :15497. doi: 10.1038/ncomms15497. PubMed PMID:28530238 PubMed Central PMC5477510.
  10. Lam, RW, Ismail, Z, MacQueen, GM, Milev, RV, Parikh, SV, Ravindran, AV et al.. Response to Letter Regarding CANMAT Recommendations for the Pharmacological Treatment of Late-life Depression. Can J Psychiatry. 2017;62 (5):353-354. doi: 10.1177/0706743717700878. PubMed PMID:28525728 PubMed Central PMC5459233.
Search PubMed

Affiliations & Other Activities

  • Physician, Department of Mental Health, St. Michael’s Hospital
  • Professor, Department of Psychiatry, University of Toronto
  • Research Scientist, Krembil Neurosciences, University Health Network